Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)

Trial Profile

Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ocular inflammation; Postoperative pain
  • Focus Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 01 Aug 2017 According to an EyeGate Pharma media release, first patient has been enrolled.
    • 01 Aug 2017 Status changed from not yet recruiting to recruiting,according to an EyeGate Pharma media release.
    • 06 Jun 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top